Clinics in Medicine and Medical Research | Volume 4, Issue 1 | Research Article | Open Access
Loso Judijanto*
IPOSS Jakarta, Indonesia
*Correspondence to: Loso Judijanto
Fulltext PDFDiabetic kidney disease (DKD) remains a major cause of chronic kidney disease and kidney failure despite substantial advances in renin–angiotensin system blockade, sodium–glucose cotransporter-2 inhibition, non-steroidal mineralocorticoid receptor antagonism and glucagon-like peptide-1 receptor agonist therapy. Persistent residual risk reflects the multifactorial biology of DKD, including oxidative stress, advanced glycation, endothelial and glycocalyx injury, mitochondrial dysfunction, podocyte loss, tubular stress, inflammation and fibrosis. Palm-derived tocotrienol-rich vitamin E has attracted interest as a potential multitarget adjunct because tocotrienols possess antioxidant, anti-inflammatory and metabolically active properties that extend beyond conventional vitamin-E radical scavenging. This qualitative translational review synthesizes post-2020 evidence relating tocotrienols to DKD pathogenesis and renal outcomes. Particular attention is given to randomized evidence reporting improvement in serum creatinine and estimated glomerular filtration rate without comparable improvement in albuminuria, creating an important mechanistic and clinical paradox. Potential explanations include compartment-specific tubular or endothelial effects, heterogeneity of DKD phenotypes, differences in temporal responsiveness of renal endpoints and limitations of creatinine-derived filtration estimates. Existing evidence remains insufficient to establish antifibrotic mechanisms, hard renal-outcome benefits or additive efficacy with contemporary renoprotective drugs. Palm tocotrienols should therefore be considered an investigational adjunct rather than established DKD therapy. Future multicenter trials should use chronic eGFR slope, albuminuria, cystatin C, tubular injury and endothelial biomarkers, inflammatory phenotyping, standardized tocotrienol formulations and stratification by contemporary drug therapy.
Diabetic kidney disease; Tocotrienols; Palm tocotrienol-rich fraction; Vitamin E; Oxidative stress; Endothelial dysfunction; Renal fibrosis; eGFR; Albuminuria; Adjunctive renoprotection
Loso Judijanto Beyond Antioxidant Supplementation: Palm Tocotrienols in Diabetic Kidney Disease—From Redox and Endothelial Injury to Preservation of Renal Function. Clin Med and Med Res. 2026;4(1):1-25.